Digital Health & AI Innovation

SHERIDAN, WYOMING – July 8, 2025 – In a landmark agreement that underscores the growing convergence of artificial intelligence and drug discovery, Tokyo-based Chugai Pharmaceutical has entered into a multi-phase research collaboration with Singapore-headquartered biotech Gero to target age-related diseases using AI-driven insights. The deal could exceed $1 billion in total value, positioning both companies at the forefront of longevity-focused pharmaceutical innovation.

AI-Powered Discovery for High-Impact Biologics

SHERIDAN, WYOMING – July 8, 2025 – A confluence of artificial intelligence and genomics is creating a critical inflection point for the pharmaceutical industry—offering a long-awaited opportunity to reduce adverse drug reactions, improve clinical outcomes, and restore public trust in a sector burdened by scrutiny and skepticism.

SHERIDAN, WYOMING – July 1, 2025 – Argenx has taken a decisive step to diversify its pipeline beyond its flagship FcRn blocker, signing a multi-target research agreement with Unnatural Products, Inc. (UNP) that could exceed $1.5 billion. The deal aims to harness UNP’s proprietary macrocyclic peptide technology to develop oral therapies for disease targets historically deemed “undruggable,” marking the largest licensing transaction to date in the macrocyclic peptide space.

Strategic Expansion Beyond FcRn Blockade

SHERIDAN, WYOMING – June 27, 2025 – In a landmark effort to expand access to high-quality oral healthcare, Dentsply Sirona, the world’s largest diversified manufacturer of professional dental products and technologies, has successfully completed a week-long dental expedition in partnership with Brazilian NGO Project 32.

SHERIDAN, WYOMING – June 24, 2025 – Dentsply Sirona has officially opened registration for DS World Las Vegas 2025, its flagship clinical education event, returning to the MGM Grand from September 25–27. Designed to empower dental professionals through innovation and knowledge-sharing, the event will spotlight Dentsply Sirona’s Connected Dentistry proposition, with a strategic focus on digital integration, workflow optimization, and patient care advancement.

Driving Practice Efficiency Through Connected Technologies

SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling new data from its ongoing FENopta open-label extension study, confirming that its investigational therapy fenebrutinib continues to provide sustained disease suppression in patients with relapsing multiple sclerosis (RMS) for up to two years.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

SHERIDAN, WYOMING – May 27, 2025 – Roche has unveiled compelling two-year follow-up data from its pivotal phase III STARGLO trial, reinforcing the long-term clinical value of Columvi® (glofitamab) in combination with chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The results underscore the strategic impact of Roche’s bispecific antibody pipeline in addressing aggressive hematologic malignancies with limited treatment options.

SHERIDAN, WYOMING – May 15, 2025 – A groundbreaking new report from Royal Philips has unveiled the immense potential of artificial intelligence (AI) to transform healthcare as we know it—if healthcare systems, providers, and patients are willing to trust it. The Future Health Index (FHI) 2025 sheds light on a stark reality: millions of people worldwide are waiting months for care, and the pressure on overburdened health workers is at a breaking point.

SHERIDAN, WYOMING – May 7, 2025 – Resmed (NYSE: RMD, ASX: RMD), a leading health technology company specializing in sleep, breathing, and home care, has announced the acquisition of VirtuOx, a prominent independent diagnostic testing facility (IDTF) focused on sleep, respiratory, and cardiac conditions. This strategic acquisition strengthens Resmed’s position in virtual care and reinforces its commitment to improving healthcare delivery by providing more accessible and coordinated care to patients and healthcare providers.